Back to News
Market Impact: 0.6

US tariffs to worsen India solar panel glut as domestic bidding slows

PEME.NSWAAN.NSADEL.NS
Tax & TariffsTrade Policy & Supply ChainRenewable Energy TransitionRegulation & LegislationEconomic DataEnergy Markets & Prices
US tariffs to worsen India solar panel glut as domestic bidding slows

New U.S. tariffs, including a 50% duty and potential anti-dumping measures, are set to severely curtail India's solar panel exports, particularly to its primary market, the U.S. This trade pressure will exacerbate India's existing domestic supply glut and low factory utilization, which currently averages 25%, pushing the nation towards significant overcapacity by 2026. Compounding these challenges, India's domestic manufacturing mandates, despite rendering its solar products significantly more expensive than Chinese alternatives, are raising generation costs and may increase reliance on Chinese cell imports before future regulations take effect.

Analysis

The Indian solar manufacturing sector faces a severe downturn driven by a confluence of external trade pressures and internal market weaknesses. A new 50% U.S. tariff, compounded by a potential anti-dumping investigation, is poised to effectively close off India's primary export market, which accounts for 90% of its module shipments. This external shock will exacerbate an already significant domestic supply glut, with forecasts indicating a state of overcapacity by 2026. Current industry health is poor, evidenced by solar module factories operating at an average of only 25% capacity. This situation is further complicated by a dramatic slowdown in domestic project awards and new tenders as of the June-ended quarter. Despite government incentives doubling production capacity to 74 GW, Indian modules remain uncompetitive globally; those using Chinese cells are 48% more expensive than Chinese equivalents, and those with Indian cells are 143% more expensive. A looming government mandate requiring domestic cell use from June 2026 threatens to escalate costs further, as Indian cells are over three times the price of Chinese alternatives, likely triggering short-term stockpiling of imported cells and creating price and supply chain volatility.

AllMind AI Terminal